• Male

Dr. J.W.J. van Heijst PhD

Position: Scientific staff member (UD)
Main activities: Research
Specialisation: Molecular Regulation of T Cell Immunity
foto
Focus of research:

The overall goal of our research is to understand at a genome-wide level how T cells provide protection against infectious diseases and cancer. Toward this goal, our work is focused in two major research lines, which are:

 

1. Molecular Regulation of Antigen-Specific T Cell Responses
It is now well established that T cells play a key protective role during both infection and cancer. However, T cells express very potent effector molecules that can also cause substantial damage to healthy tissues, and therefore several regulatory mechanisms have evolved to inhibit T cell functionality. The downside of this T cell inhibition is that it can eventually facilitate the persistence of pathogens or tumour cells, thereby aiding the development of chronic infections and cancer. So, to help treat diseases such as Tuberculosis, HIV/AIDS or Melanoma, there is now a large demand for novel therapeutic strategies to block T cell inhibition. In this context, we have recently identified a new inhibitory mechanism of T cell responses that operates via the sustained downregulation of T cell antigen receptor expression in a graded avidity-dependent manner. Currently, we are investigating the molecular pathways driving this sustained T cell antigen receptor downregulation, ultimately aiming to maximize the therapeutic potential of T cell responses.


2. Host and Pathogen Factors in Protective Immunity to Tuberculosis
Tuberculosis remains a top 10 cause of death worldwide and has been very difficult to control due to an increase in drug-resistant strains and the absence of an effective vaccine. A major obstacle for successful vaccine development is the lack of clear immune correlates of protection. Unravelling the mechanistic basis of protective T cell responses has proven highly challenging, primarily due to a lack of suitable experimental models. To address these limitations, we have developed a new protection model amenable to high-throughput genetic manipulation, using transgenic Mycobacterium tuberculosis-specific CD4+ T cells. We are currently combining this model with adoptive cell transfers and functional genomics tools to elucidate the T cell-mycobacterial interplay at the primary site of disease, the lung. Understanding protective immune mechanisms in tuberculosis will provide new avenues to target this refractory infectious killer.


For contact and enquiries, please send an e-mail to: j.w.vanheijst@amc.nl


AMC themes: Infection & Immunity
Departments: Experimental Immunology
Benichou JIC, van Heijst JWJ, Glanville J, Louzoun Y, Converging evolution leads to near maximal junction diversity through parallel mechanisms in B and T cell receptors. PHYS BIOL 2017;14 (4):045003 [PubMed]
Anas AA, de Vos AF, Hoogendijk AJ, van Lieshout MHP, van Heijst JWJ, Florquin S, Li Z, van 't Veer C, van der Poll T, Endoplasmic reticulum chaperone gp96 in macrophages is essential for protective immunity during Gram-negative pneumonia. J PATHOL 2016;238 (1):74-84 [PubMed]
Gallegos AM, Xiong H, Leiner IM, Sušac B, Glickman MS, Pamer EG, van Heijst JWJ, Control of T cell antigen reactivity via programmed TCR downregulation. NAT IMMUNOL 2016;17 (4):379-386 [PubMed]
Gerlach C, Rohr JC, Perié L, van Rooij N, van Heijst JWJ, Velds A, Urbanus J, Naik SH, Jacobs H, Beltman JB, de Boer RJ, Schumacher TNM, Heterogeneous differentiation patterns of individual CD8+ T cells. SCIENCE 2013;340 (6132):635-639 [PubMed]
van Heijst JWJ, Ceberio I, Lipuma LB, Samilo DW, Wasilewski GD, Gonzales AMR, Nieves JL, van den Brink MRM, Perales MA, Pamer EG, Quantitative assessment of T cell repertoire recovery after hematopoietic stem cell transplantation. NAT MED 2013;19 (3):372-377 [PubMed]
van Heijst JWJ, Pamer EG, Radical host-specific therapies for TB. CELL 2013;153 (3):507-508 [PubMed]
Gallegos AM, van Heijst JWJ, Samstein M, Su X, Pamer EG, Glickman MS, A gamma interferon independent mechanism of CD4 T cell mediated control of M. tuberculosis infection in vivo. PLOS PATHOG 2011;7 (5):e1002052 [PubMed]
Gerlach C, van Heijst JWJ, Schumacher TNM, The descent of memory T cells. ANN NY ACAD SCI 2011;1217:139-153 [PubMed]
Gerlach C, van Heijst JWJ, Swart E, Sie D, Armstrong N, Kerkhoven RM, Zehn D, Bevan MJ, Schepers K, Schumacher TNM, One naive T cell, multiple fates in CD8+ T cell differentiation. J EXP MED 2010;207 (6):1235-1246 [PubMed]
Schumacher TNM, Gerlach C, van Heijst JWJ, Mapping the life histories of T cells. NAT REV IMMUNOL 2010;10 (9):621-631 [PubMed]
van Heijst JWJ, Gerlach C, Swart E, Sie D, Nunes-Alves C, Kerkhoven RM, Arens R, Correia-Neves M, Schepers K, Schumacher TNM, Recruitment of antigen-specific CD8+ T cells in response to infection is markedly efficient. SCIENCE 2009;325 (5945):1265-1269 [PubMed]
Coccoris M, Swart E, de Witte MA, van Heijst JWJ, Haanen JBAG, Schepers K, Schumacher TNM, Long-term functionality of TCR-transduced T cells in vivo. J IMMUNOL 2008;180 (10):6536-6543 [PubMed]
Schepers K, Swart E, van Heijst JWJ, Gerlach C, Castrucci M, Sie D, Heimerikx M, Velds A, Kerkhoven RM, Arens R, Schumacher TNM, Dissecting T cell lineage relationships by cellular barcoding. J EXP MED 2008;205 (10):2309-2318 [PubMed]
van Heijst JWJ, Niessen HWM, Musters RJ, van Hinsbergh VWM, Hoekman K, Schalkwijk CG, Argpyrimidine-modified Heat shock protein 27 in human non-small cell lung cancer: a possible mechanism for evasion of apoptosis. CANCER LETT 2006;241 (2):309-319 [PubMed]
van Heijst JWJ, Niessen HWM, Hoekman K, Schalkwijk CG, Advanced glycation end products in human cancer tissues: detection of Nepsilon-(carboxymethyl)lysine and argpyrimidine. ANN NY ACAD SCI 2005;1043:725-733 [PubMed]
Key publications

Gallegos AM, Xiong H, Leiner IM, Sušac B, Glickman MS, Pamer EG, van Heijst JWJ, Control of T cell antigen reactivity via programmed TCR downregulation. NAT IMMUNOL 2016;17 (4):379-386 [PubMed]
van Heijst JWJ, Pamer EG, Radical host-specific therapies for TB. CELL 2013;153 (3):507-508 [PubMed]
van Heijst JWJ, Ceberio I, Lipuma LB, Samilo DW, Wasilewski GD, Gonzales AMR, Nieves JL, van den Brink MRM, Perales MA, Pamer EG, Quantitative assessment of T cell repertoire recovery after hematopoietic stem cell transplantation. NAT MED 2013;19 (3):372-377 [PubMed]
Schumacher TNM, Gerlach C, van Heijst JWJ, Mapping the life histories of T cells. NAT REV IMMUNOL 2010;10 (9):621-631 [PubMed]
van Heijst JWJ, Gerlach C, Swart E, Sie D, Nunes-Alves C, Kerkhoven RM, Arens R, Correia-Neves M, Schepers K, Schumacher TNM, Recruitment of antigen-specific CD8+ T cells in response to infection is markedly efficient. SCIENCE 2009;325 (5945):1265-1269 [PubMed]


All Publications

Curriculum Vitae

Professional experience:

2017 - present Group leader (assistant professor), Department of Experimental Immunology, AMC, Amsterdam.

2013 - 2017 Postdoctoral fellow, Center of Experimental and Molecular Medicine, AMC, Amsterdam.

2010 - 2013 Postdoctoral fellow, Immunology program, MSKCC, New York.

2004 - 2010 PhD student, Division of Immunology, NKI, Amsterdam.

 

Education:

2010 Doctoral degree, Leiden University, Leiden. Thesis: Tracing T cell differentiation by genetic barcoding.

2004 Master’s degree (cum laude), VU University, Amsterdam. Main topic: Oncology.

 

Fellowships & Awards:

- NWO Vidi grant, Netherlands Organisation for Scientific Research, 2017

- NWO Veni grant, Netherlands Organisation for Scientific Research, 2013

- NVVI PhD thesis award, Dutch Society for Immunology, 2010

- EMBO Long-term fellowship, European Molecular Biology Organization, 2010

- NWO Rubicon fellowship, Netherlands Organisation for Scientific Research, 2010

 

Research programmes

Prof. dr. T. van der Poll (Pathophysiology of sepsis)

Other research related activities
  • None reported
Current research funding
  • ZonMw